This invention discloses the application of a branched-chain
amino acid (BCAA) restricted diet in the preparation of drugs for treating liver metastases of tumors. Through mouse model experiments, this invention found that restricting the intake of BCAAs (
valine,
isoleucine, and
leucine) in the diet, or using the SCD1 inhibitor A939572, can significantly inhibit liver metastases of tumors, especially
pancreatic cancer liver metastases. Experimental results show that a BCAA restricted diet or SCD1 inhibitor can reduce the number and volume of liver metastases and inhibit their growth. This invention also reveals its
mechanism of action: BCAA restriction reduces the propionylation modification of SREBP1, downregulates the
transcriptional expression of its
target gene SCD1, and thus reduces lipid synthesis, thereby exerting an anti-tumor liver
metastasis effect. This invention provides a novel dietary intervention strategy and
drug target for the treatment of liver metastases of tumors.